LENZ
What one share of Lenz Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision.
Lenz Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.70 |
|---|---|
| Profit | −$4.12 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.74 |
| Cash and investments | $0.77 |
| Book value | $6.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$29.93 | $0.68 | −$4.49 | — | — |
| 2021 | — | −$2.45 | $0.20 | −$2.03 | — | — |
| 2022 | — | −$1.84 | $0.12 | −$1.72 | — | −$0.42 |
| 2023 | — | −$35.71 | $0.02 | −$30.84 | — | −$47.08 |
| 2024 | $0.00 | −$2.34 | $0.02 | −$2.81 | — | $7.42 |
| 2025 | $0.66 | −$2.85 | $0.03 | −$2.43 | — | $9.07 |